We are live on ! Find out more
KAM

Krensavage Asset Management Portfolio holdings

AUM $256M
1-Year Est. Return 69.63%
This Fund
S&P 500
This Quarter Est. Return
-2.51%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$272M
AUM Growth
-$44M
Cap. Flow
-$28M
Cap. Flow %
-10.32%
Top 10 Hldgs %
99.2%
Holding
12
New
–
Increased
2
Reduced
10
Closed
–

Top Buys

Rank Stock Value
1
EMBC icon
Embecta
EMBC
+$1.76M
2
ENTA icon
Enanta Pharmaceuticals
ENTA
+$765K

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.38M
2
ALKS icon
Alkermes
ALKS
+$5.79M
3
CAH icon
Cardinal Health
CAH
+$5.64M
4
EXEL icon
Exelixis
EXEL
+$4.91M
5
BIIB icon
Biogen
BIIB
+$4.37M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$25.8B
$45.5M 16.73%
201,222
-1,493
-0.7% -$344K
EXEL icon
2
Exelixis
EXEL
$13.3B
$41.5M 15.28%
1,899,151
-234,552
-11% -$4.91M
BIIB icon
3
Biogen
BIIB
$30B
$41.2M 15.19%
160,480
-16,346
-9% -$4.37M
REGN icon
4
Regeneron Pharmaceuticals
REGN
$78.5B
$38.9M 14.32%
47,256
-11,932
-20% -$9.38M
ALKS icon
5
Alkermes
ALKS
$8.22B
$25.4M 9.34%
906,060
-197,391
-18% -$5.79M
CAH icon
6
Cardinal Health
CAH
$53.9B
$25.3M 9.31%
291,319
-62,395
-18% -$5.64M
TARO
7
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$24.2M 8.9%
640,735
-2,345
-0.4% -$88K
EMBC icon
8
Embecta
EMBC
$216M
$17.5M 6.45%
1,164,876
+94,066
+9% +$1.76M
ENTA icon
9
Enanta Pharmaceuticals
ENTA
$366M
$8.21M 3.02%
735,103
+47,490
+7% +$765K
EGRX
10
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$1.78M 0.65%
112,666
-771
-0.7% -$13.9K
VNDA icon
11
Vanda Pharmaceuticals
VNDA
$307M
$1.56M 0.57%
360,429
-2,522
-0.7% -$14K
KOD icon
12
Kodiak Sciences
KOD
$2.6B
$616K 0.23%
342,312
-2,322
-0.7% -$8.19K

Similar funds

CIA
Corigliano Investment Advisers Raleigh, North Carolina $256M AUM 54.89% 1-Year Est. Return
2
2Xideas Kusnacht, Switzerland $255M AUM 0.46% 1-Year Est. Return
CIM
Caldwell Investment Management Toronto, Ontario, Canada $255M AUM 36.87% 1-Year Est. Return
JFG
Juno Financial Group Richmond, Virginia $255M AUM
PIP
Palisades Investment Partners Santa Monica, California $255M AUM 50.52% 1-Year Est. Return
LRIC
Long Road Investment Counsel Kalamazoo, Michigan $255M AUM 12.85% 1-Year Est. Return
GAMC
Garner Asset Management Corp Plano, Texas $255M AUM 22.93% 1-Year Est. Return
TIA
Tiemann Investment Advisors Menlo Park, California $255M AUM 21.35% 1-Year Est. Return

Krensavage Asset Management's Q3 2023 Portfolio in Review

As of Q3 2023, Krensavage Asset Management held 12 positions worth $272M, down 14% from $316M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Krensavage Asset Management withdrew a net $28M in Q3 2023, reducing 10 holdings. Its largest reduction was Regeneron Pharmaceuticals, cutting an estimated $9.38M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Krensavage Asset Management added an estimated $1.76M to Embecta.

  • Krensavage Asset Management added most to Embecta in Q3 2023, an estimated $1.76M increase.
  • Krensavage Asset Management's biggest Q3 2023 reduction was Regeneron Pharmaceuticals, cutting an estimated $9.38M.
  • Krensavage Asset Management's ten largest holdings make up 99% of its $272M portfolio in Q3 2023.
  • Krensavage Asset Management opened 0 new positions and closed 0 in Q3 2023.
  • Krensavage Asset Management's portfolio value fell 14% quarter-over-quarter to $272M.

Based on Krensavage Asset Management's 13F filing for Q3 2023, filed 15 Nov 2023.